← Back to Clinical Trials
Recruiting NCT03610763

NCT03610763 Harnessing Neuroplasticity to Enhance Functional Recovery During Chronic Recovery From Upper Extremity Nerve Repair

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03610763
Status Recruiting
Phase
Sponsor University of Missouri-Columbia
Condition Hand Transplantation
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2018-08-15
Primary Completion 2025-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Transcranial Direct Current StimulationModified Constraint Induced Movement Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2018-08-15 with a primary completion date of 2025-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study adopts a strategy that has arisen from basic neuroscience research on facilitating adaptive brain plasticity and applies this to rehabilitation to improve functional recovery in peripheral nervous system injuries (including hand transplantation, hand replantation, and surgically repaired upper extremity nerve injuries). The technique involves combining behavioral training with transcranial direct current stimulation (tDCS)-a non-invasive form of brain stimulation capable of facilitating adaptive changes in brain organization.

Eligibility Criteria

Inclusion Criteria: * Individuals whom have received a unilateral allogeneic transplantation proximal to the wrist and are at the chronic stage of recovery (approx. 12 - 18 months following surgery, when Tinel's sign reaches the distal fingertips). * Individuals whom have undergone a complete amputation the hand between the wrist and elbow followed by successful re-attachment and are at the chronic stage of recovery (approx. 12 - 18 months following surgery, when Tinel's sign reaches the distal fingertips). * Individuals whom have undergone repairs of the median, ulnar, or other related or nearby nerve(s) following complex volar forearm lacerations or other injuries between the distal wrist crease and the flexor musculotendinous junctions. Individuals must be at the chronic stage of recovery (approx. 12 - 18 months following surgery, when Tinel's sign reaches the distal fingertips). Exclusion Criteria: * Individuals with significant/severe brain trauma * Serious psychiatric conditions * Chronic or severe neurological conditions. * Current pregnancy * History of seizures or unexplained loss of consciousness * Metallic implants above the chest * Certain implanted medical devices.

Contact & Investigator

Central Contact

Scott H Frey, Ph.D., Ed.M.

✉ freylab@missouri.edu

📞 573-882-4572

Principal Investigator

Scott H Frey, Ph.D., Ed.M.

PRINCIPAL INVESTIGATOR

University of Missouri-Columbia

Frequently Asked Questions

Who can join the NCT03610763 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hand Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03610763 currently recruiting?

Yes, NCT03610763 is actively recruiting participants. Contact the research team at freylab@missouri.edu for enrollment information.

Where is the NCT03610763 trial being conducted?

This trial is being conducted at Louisville, United States, Columbia, United States, St Louis, United States.

Who is sponsoring the NCT03610763 clinical trial?

NCT03610763 is sponsored by University of Missouri-Columbia. The principal investigator is Scott H Frey, Ph.D., Ed.M. at University of Missouri-Columbia. The trial plans to enroll 180 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology